Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota
Applied Microbiology and Biotechnology · 2024-12 · 108 (1)
DOI: 10.1007/s00253-024-13280-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 19.09.2024. Verfasst von Yijia Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Rifaximin, Lung, Orthomyxoviridae Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Xinjiang Animal Disease Prevention and Control Engineering Technology Research Center.
Abstract (Originalsprache)
Prior research has indicated that the gut-lung-axis can be influenced by the intestinal microbiota, thereby impacting lung immunity. Rifaximin is a broad-spectrum antibacterial drug that can maintain the homeostasis of intestinal microflora. In this study, we established an influenza A virus (IAV)-infected mice model with or without rifaximin supplementation to investigate whether rifaximin could ameliorate lung injury induced by IAV and explore the molecular mechanism involved. Our results showed that IAV caused significant weight loss and disrupted the structure of the lung and intestine. The analysis results of 16S rRNA and metabolomics indicated a notable reduction in the levels of probiotics Lachnoclostridium, Ruminococcaceae_UCG-013, and tryptophan metabolites in the fecal samples of mice infected with IAV. In contrast, supplementation with 50 mg/kg rifaximin reversed these changes, including promoting the repair of the lung barrier and increasing the abundance of Muribaculum, Papillibacter and tryptophan-related metabolites content in the feces. Additionally, rifaximin treatment increased ILC3 cell numbers, IL-22 level, and the expression of RORγ and STAT-3 protein in the lung. Furthermore, our findings demonstrated that the administration of rifaximin can mitigate damage to the intestinal barrier while enhancing the expression of AHR, IDO-1, and tight junction proteins in the small intestine. Overall, our results provided that rifaximin alleviated the imbalance in gut microbiota homeostasis induced by IAV infection and promoted the production of tryptophan-related metabolites. Tryptophan functions as a signal to facilitate the activation and movement of ILC3 cells from the intestine to the lung through the AHR/STAT3/IL-22 pathway, thereby aiding in the restoration of the barrier. KEY POINTS: • Rifaximin ameliorated IAV infection-caused lung barrier injury and induced ILC3 cell activation. • Rifaximin alleviated IAV-induced gut dysbiosis and recovered tryptophan metabolism. • Tryptophan mediates rifaximin-induced ILC3 cell activation via the AHR/STAT3/IL-22 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China.
- Institute of Veterinary Medicine, Xinjiang Academy of Animal Science, Urumqi, 830013, China.
- MOE Joint International Research Laboratory of Animal Health and Food Safety, Engineering Laboratory of Animal Immunity of Jiangsu Province, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 2100…
- Laboratory of Animal Neurobiology, College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, 210095, China. sujuan@njau.edu.cn.
Förderung
- National Natural Science Foundation of China
- Xinjiang Animal Disease Prevention and Control Engineering Technology Research Center
Zitieren
APA
Zhang, Y., Chen, Y., Xia, J., Li, L., Chang, L., Luo, H., Ping, J., Qiao, W., & Su, J. (2024). Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-024-13280-6
Vancouver
Zhang Y, Chen Y, Xia J, Li L, Chang L, Luo H, et al. Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-024-13280-6
BibTeX
@article{Zhang2024,
author = {Zhang, Yijia and Chen, Yafei and Xia, Jun and Li, Li and Chang, Lifeng and Luo, Haowei and Ping, Jihui and Qiao, Wenna and Su, Juan},
title = {Rifaximin ameliorates influenza A virus infection-induced lung barrier damage by regulating gut microbiota},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
volume = {108},
number = {1},
doi = {10.1007/s00253-024-13280-6}
}
EUVIMED